domains / families / science / adaptive-designs

adaptive-designs

separate

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

When to use

• group-sequential designs
• sample-size re-estimation
• seamless Phase 2/3 with treatment-arm selection
• population enrichment
• response-adaptive randomisation
• planning interim analyses
• master/platform-trial designs

Skill page

Source